GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (NYSE:JNJ) » Definitions » Cyclically Adjusted PS Ratio

JNJ (Johnson & Johnson) Cyclically Adjusted PS Ratio : 4.23 (As of May. 27, 2025)


View and export this data going back to 1944. Start your Free Trial

What is Johnson & Johnson Cyclically Adjusted PS Ratio?

As of today (2025-05-27), Johnson & Johnson's current share price is $153.25. Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $36.19. Johnson & Johnson's Cyclically Adjusted PS Ratio for today is 4.23.

The historical rank and industry rank for Johnson & Johnson's Cyclically Adjusted PS Ratio or its related term are showing as below:

JNJ' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.75   Med: 4.91   Max: 5.9
Current: 4.23

During the past years, Johnson & Johnson's highest Cyclically Adjusted PS Ratio was 5.90. The lowest was 3.75. And the median was 4.91.

JNJ's Cyclically Adjusted PS Ratio is ranked worse than
73.68% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs JNJ: 4.23

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Johnson & Johnson's adjusted revenue per share data for the three months ended in Mar. 2025 was $9.033. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $36.19 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Johnson & Johnson Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Johnson & Johnson's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Cyclically Adjusted PS Ratio Chart

Johnson & Johnson Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.46 5.52 5.32 4.55 4.06

Johnson & Johnson Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.51 4.13 4.56 4.06 4.58

Competitive Comparison of Johnson & Johnson's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Cyclically Adjusted PS Ratio falls into.


;
;

Johnson & Johnson Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Johnson & Johnson's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=153.25/36.19
=4.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Johnson & Johnson's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=9.033/134.9266*134.9266
=9.033

Current CPI (Mar. 2025) = 134.9266.

Johnson & Johnson Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 6.325 100.684 8.476
201509 6.092 100.392 8.188
201512 6.360 99.792 8.599
201603 6.235 100.470 8.373
201606 6.614 101.688 8.776
201609 6.398 101.861 8.475
201612 6.546 101.863 8.671
201703 6.450 102.862 8.461
201706 6.872 103.349 8.972
201709 7.178 104.136 9.300
201712 7.365 104.011 9.554
201803 7.324 105.290 9.386
201806 7.654 106.317 9.714
201809 7.460 106.507 9.451
201812 7.481 105.998 9.523
201903 7.418 107.251 9.332
201906 7.639 108.070 9.537
201909 7.764 108.329 9.670
201912 7.762 108.420 9.660
202003 7.747 108.902 9.598
202006 6.879 108.767 8.533
202009 7.898 109.815 9.704
202012 8.416 109.897 10.333
202103 8.351 111.754 10.083
202106 8.726 114.631 10.271
202109 8.725 115.734 10.172
202112 3.656 117.630 4.194
202203 8.785 121.301 9.772
202206 9.003 125.017 9.717
202209 7.514 125.227 8.096
202212 7.515 125.222 8.097
202303 8.019 127.348 8.496
202306 8.196 128.729 8.591
202309 8.374 129.860 8.701
202312 8.799 129.419 9.173
202403 8.799 131.776 9.009
202406 9.268 132.554 9.434
202409 9.255 133.029 9.387
202412 9.271 133.157 9.394
202503 9.033 134.927 9.033

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Johnson & Johnson  (NYSE:JNJ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Johnson & Johnson Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson Business Description

Address
One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Executives
Robert J Decker officer: Controller, CAO ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Timothy Schmid officer: EVP, WW Chair, MedTech ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Joseph J Wolk officer: Exec VP, CFO JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Mark A Weinberger director METLIFE, INC., 200 PARK AVENUE, NEW YORK NY 10166
Vanessa Broadhurst officer: EVP, Global Corp Aff. ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jennifer L Taubert officer: EVP, WW Chair, Pharmaceuticals JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
William Hait officer: See Remarks ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Peter Fasolo officer: VP, Worldwide Human Resources JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Kathryn E Wengel officer: EVP, Chief GSC Officer JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
John C Reed officer: EVP, Pharmaceuticals R&D ONE JOHNSON & JOHNSON PLAZA, WHQ 2134, NEW BRUNSWICK NJ 08933
James D. Swanson officer: EVP, Chief Information Officer ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Paula A Johnson director 22 CHERRY HILL DRIVE, DANVERS MA 01923
Ashley Mcevoy officer: EVP, WW Chair, Medical Devices JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Thibaut Mongon officer: Exec VP, WW Chair, Consumer JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Elizabeth Forminard officer: Executive VP, General Counsel ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933